Pseudomonas aeruginosa and Burkholderia cepacia cause destructive lung disease in cystic fibrosis (CF) patients. Both pathogens emploỳ quorum sensing', i.e. cell-to-cell communication, via diffusible N-acyl-L-homoserine lactone (AHL) signal molecules, to regulate the production of a number of virulence determinants in vitro. However, to date, evidence that quorum sensing systems are functional and play a role in vivo is lacking. This study presents the first direct evidence for the presence of AHLs in CF sputum. A total of 42 samples from 25 CF patients were analysed using lux-based Escherichia coli AHL biosensors. AHLs were detected in sputum from patients colonised by P. aeruginosa or B. cepacia but not Staphylococcus aureus. Furthermore, using liquid chromatography-mass spectrometry and thin layer chromatography, we confirmed the presence of N-hexanoylhomoserine lactone and N-(3-oxododecanoyl)homoserine lactone respectively in sputum samples from patients colonised by P. aeruginosa. ß
Introduction
Cystic ¢brosis (CF) is a genetic disease characterised by mucus hyper-secretion, chronic bacterial infection and airway in£ammation. Microbial colonisation of the major airways of CF patients by Pseudomonas aeruginosa, Burkholderia cepacia and Staphylococcus aureus leads to destructive lung disease. This is the major cause of morbidity and mortality in CF patients (for review see [1] ), requiring frequent physiotherapy and aggressive treatment with antibacterial drugs.
In recent years it has been established that many di¡er-ent bacteria co-ordinate gene expression in a cell densitydependent manner using small di¡usible signalling molecules, a phenomenon termed`quorum sensing' [2^4] . In Gram-negative bacteria, the most intensively studied quorum sensing systems utilise N-acylhomoserine lactones (AHLs) as inter-cellular signalling molecules, the synthesis of which is mediated by a LuxI-type protein. In these organisms, a transcriptional regulator protein (LuxRtype) acts in conjunction with the cognate AHL to regulate target gene expression. Of particular relevance, the two major CF pathogens P. aeruginosa [5^8] and B. cepacia [9] are both known to regulate virulence gene expression via AHLs in vitro.
P. aeruginosa possesses two quorum sensing systems employing the LuxRI homologues LasRI and RhlR (VsmRI), with the major cognate signal molecules being N-(3-oxododecanoyl)-L-homoserine lactone (3-oxo-C 12 -HSL), N-butanoyl-L-homoserine lactone (C 4 -HSL) and N-hexanoyl-L-homoserine lactone (C 6 -HSL) [7^13] . Importantly, cell^cell signalling in P. aeruginosa is involved in the regulation of a number of virulence determinants, such as elastase, which contribute to the deterioration of lung function in colonised CF patients [8, 14, 15] . In another important CF pathogen, B. cepacia, the production of both exoprotease and the siderophore, ornibactin, are regulated by CepR and its cognate AHL, N-octanoyl-Lhomoserine lactone (C 8 -HSL). Interestingly, it has been shown that CF isolates of P. aeruginosa and B. cepacia produce AHLs in vitro [16, 17] . Furthermore, indirect evidence for AHL production in CF sputum containing P. aeruginosa was obtained by Singh et al. [18] . They used 14 C-labelled methionine, which is incorporated into AHLs via S-adenosylmethionine during AHL biosynthesis, to show in cystic ¢brosis sputa (incubated ex vivo for 4 h to stimulate de novo AHL biosynthesis), P. aeruginosa produces AHLs. More direct evidence for AHL production by P. aeruginosa in vivo has come from studies of lung infections in mice in which P. aeruginosa was co-inoculated with a recombinant Escherichia coli AHL biosensor carrying a luxRIP: :gfp reporter fusion [19] .
In this paper we present direct evidence that AHLs are produced in CF sputum during P. aeruginosa and B. cepacia lung infections by using sensitive recombinant E. coli-based AHL biosensors. Furthermore, we have con¢rmed the nature of the AHLs present in CF sputum colonised by P. aeruginosa using thin layer chromatography (TLC) and high resolution mass spectrometry.
Materials and methods

Patient data
Patients were recruited from the Adult CF Unit (City Hospital, Nottingham, UK) between July 1998 and August 1999. All had elevated sweat sodium ( s 60 mmol l 31 ) and chloride ( s 70 mmol l 31 ) concentrations as well as clinical and radiological features consistent with the diagnosis of cystic ¢brosis with a median FEV 1 of 1.8 (range 0.55^4.00), FVC of 3.0 (0.9^5.1). The genotype of 15/25 patients was known: six patients were homozygous for vF508, seven patients had vF508 the other mutation being unknown and there were two patients with vF508/621+1 G s T and G551D/621+1 G s T respectively. A total of 42 sputum samples were taken from 25 CF patients (median age 22 years, range 17^37). Sputum samples were collected from stable CF patients attending out-patient clinic who were not taking oral or intravenous antibiotics. Patients were colonised with either P. aeruginosa (17 patients), B. cepacia (four patients) or S. aureus (four patients). Sputum samples were stored on ice during transportation and processed to determine the presence of AHL(s) on the same day they were obtained from the patient.
Bacterial strains and growth conditions
P. aeruginosa were isolated from sputum by streaking on Pseudomonas Isolation Agar (PIA) (Difco, US) whereas S. aureus and B. cepacia were isolated on Luria^Bertani agar (LB). All isolates were then incubated at 37³C overnight. AHL biosensor strains were grown at 30³C overnight in LB broth. For plasmid maintenance E. coli JM109 (pSB401) and E. coli JM109 (pSB1075) were grown in LB broth containing 10 Wg ml 31 tetracycline.
Detection of AHLs in sputum
Sputum samples were diluted to 10 ml with sterile phosphate-bu¡ered saline (PBS) pH 7.4, centrifuged (10 000 rpm for 10 min; Beckman Avanti 30 centrifuge, rotor CO650), to remove any debris. The resulting diluted sputum supernatants were extracted using a modi¢ed protocol of Cämara et al. [20] . Essentially, supernatants were extracted twice using equal volumes of dichloromethane and evaporated to dryness using a rotary evaporator (Buchi R-114, Switzerland). The extract was reconstituted in 50 Wl of acetonitrile and stored at 320³C. Two E. coli biosensor strains containing lux-based bioluminescence AHL reporter plasmids were used to detect the presence of AHLs in concentrated solvent extracts. The reporter plasmid pSB401 [21] , contains the Vibrio ¢scheri luxR gene and luxI promoter fused to luxCDABE from Photorhabdus luminescens. When introduced into E. coli JM109, this construct responds preferentially to the presence of exogenously added AHLs with acyl chains from six to eight carbons in length such as N-(3-oxohexanoylhomoserine) lactone (3-oxo-C 6 -HSL) and C 6 -HSL and C 8 -HSL by the emission of light. For detection of long chain AHLs such as 3-oxo-C 12 -HSL, E. coli JM109 harbouring the reporter plasmid pSB1075 [21] was used. This reporter contains the P. aeruginosa lasR gene and lasI promoter fused to luxCDABE from P. luminescens and preferentially responds to AHLs with acyl chains of 10^14 carbons in length. In all cases, light emission was detected using a Berthold LB980 photon video camera (E.G. and G. Berthold UK Ltd, Milton Keynes, UK). AHL bioassays, using the E. coli lux-based reporters, were performed in microtitre well plates as described previously [20] . Brie£y, 10 Wl of the sputum extract was added to 90 Wl of the sensor strain culture, after which doubling dilutions were performed in a microtitre well plate, using LB as the diluent. Similar doubling dilutions were performed on synthetic standards (10 Wl of 10 Wg ml 31 synthetic 3-oxo-C 6 -HSL or 3-oxo-C 12 -HSL) and used as positive controls. Light emission was observed following overnight incubation at 30³C. The investigator performing the AHL assay was blinded to the patient clinical data.
Identi¢cation of AHLs
TLC was employed to separate AHLs and overlaid with soft top agar seeded with the appropriate biosensor strain as described by McClean et al. [22] . Brie£y, for analysis of short chain AHLs, reverse phase aluminium-backed RP18 F 254S TLC plates (20 cmU20 cm ; Merck) and a mobile phase of 60% v/v methanol in water were employed. Long chain AHLs were analysed on aluminium-backed Silicagel 60 F 254 normal phase TLC plates (20 cmU20 cm; Merck) using a 45:55% v/v hexane:acetone mix as the mobile phase.
AHLs detected by TLC were puri¢ed and characterised as described [5, 20, 23] . Essentially, AHLs from sputum extracts were puri¢ed by semi-preparative reverse-phase high pressure liquid chromatography (HPLC) (Kromasil KR100-5C8 [250U8 mm] column; Hichrom, Reading, UK). Fractions were eluted with a linear gradient of acetonitrile in water (20^95%) over a 30-min period at a £ow rate of 2 ml min 31 and monitored at 210 nm. Six fractions (F1^F6) were collected, covering 5-min intervals, and assayed for activity using the E. coli lux-based biosensors. Following preparative HPLC, the active fractions were analysed by HPLC-mass spectrometry (LC-MS) (Micromass Instruments, Manchester, UK) as described previously [24] . The spectra obtained were compared with those for synthetic AHL standards subjected to the same LC-MS conditions.
Synthesis of AHLs
The synthesis of AHLs was done as previously described [20, 25] .
Results
Detection of AHL signalling molecules in sputum from
CF patients colonised by P. aeruginosa and B. cepacia
To obtain direct evidence that AHLs are produced in vivo in the CF lung of patients colonised by P. aeruginosa and B. cepacia, sputum samples were extracted with dichloromethane and assayed for the presence of AHLs using the lux-based biosensor strains E. coli (pSB401) and E. coli (pSB1075) in microtitre well plates. The use of these strains allows detection of most AHLs which have so far been described in Gram-negative bacteria including those of P. aeruginosa and B. cepacia [17, 21] . The emission of light by both E. coli (pSB401) and E. coli (pSB1075) when incubated with di¡erent sputum samples indicates the presence of AHLs, with di¡erent acyl side chain lengths ( Fig. 1; Table 1) .
Using E. coli (pSB401) AHLs were detected in 30 out of 42 samples (71%) ( Table 1 ) whereas only 26 samples (61%) activated E. coli (pSB1075). Similarly, sputum extracts from B. cepacia-colonised patients activated E. coli (pSB401) in seven out of eight samples (87%) and E. coli (pSB1075) in four out of eight samples (50%). An example of a typical microtitre plate bioassay result, obtained using a photon imaging camera, is shown in Fig. 1 . As anticipated, solvent extracts of sputum obtained from patients colonised by S. aureus did not activate either biosensor as this organism has not been shown to produce AHLs in vitro [3] . Therefore, sputum samples from S. aureus-colonised patients acted as an appropriate negative control in this study. Fig. 1 . Photon camera image of extracts of sputum from patients colonised by P. aeruginosa and B. cepacia screened for the presence of AHLs using (A) the luxR-based biosensor E. coli (pSB401) and (B) the lasRbased AHL biosensor E. coli (pSB1075). Doubling dilutions of sputum extracts were performed from left to right in a microtitre well plate and then incubated with 100 Wl of either E. coli (pSB401) or E. coli (pSB1075). 1, 2 and 4: sputum extracts from P. aeruginosa-colonised patients ; 3: sputum extract from a B. cepacia-colonised patient. +ve (positive control): 10 Wl of 10 Wg ml 31 3-oxo-C 6 -HSL (A); 10 Wl of 10 Wg ml 31 3-oxo-C 12 -HSL (B); -ve (negative control): 10 Wl of acetonitrile in LB broth. Table 1 Summary of results from AHL microtitre well plate bioassays used to detect AHLs in sputum extracts from patients colonised by P. aeruginosa, B. cepacia and S. aureus
Colonising organism
Number of patients Number of samples Number of samples activating bioassay The E. coli (pSB401) and E. coli (pSB1075) biosensors are used to detect AHLs with short and long acyl side chains respectively.
Identi¢cation of AHLs in sputum samples from P. aeruginosa-colonised patients by TLC and LC-MS
The activation of both E. coli (pSB401) and E. coli (pSB1075) by extracts from sputum samples taken from both P. aeruginosa-and B. cepacia-colonised patients suggested that a range of AHL molecules were present in these samples. As a consequence of the limited availability of infected sputum samples, only extracts from sputum samples containing P. aeruginosa were subjected to detailed chemical analysis. These extracts were separated by TLC and then overlaid with E. coli (pSB401) (data not shown) and E. coli (pSB1075) (Fig. 2 ). An active compound with the same migration as the synthetic 3-oxo-C 12 -HSL standard was observed in extracts of sputum from P. aeruginosa-colonised patients using the E. coli (pSB1075) biosensor strain (Fig. 2) . This active compound also showed a tailing e¡ect characteristic of AHLs possessing a 3-oxo substituent in the acyl side chain. Furthermore, it was con¢rmed that the colonising P. aeruginosa strains produced 3-oxo-C 12 -HSL, C 4 -HSL and C 6 -HSL in vitro, by performing similar AHL analyses on extracts of cellfree supernatants of laboratory-grown cultures using E. coli lux-based AHL biosensors as described before [8] (data not shown).
To con¢rm the identity of AHLs detected in sputum extracts using E. coli (pSB401) or E. coli (pSB1075), LC-MS was employed. Unfortunately, identi¢cation of AHLs in individual extracts proved unsuccessful due to the small quantities of sputum available. Therefore, seven sputum samples from the same patient colonised with P. aeruginosa, and which TLC analysis indicated contained AHLs, were pooled and concentrated. AHLs in the pooled extract were ¢rst separated by HPLC and the subsequent fractions assayed for activity against the AHL biosensors. Active fractions were then subjected to LC-MS analysis. The LC-MS spectrum obtained for the active molecule present in fraction 3 (Fig. 3) , in which synthetic C 6 -HSL is expected to elute, revealed a molecular ion of 200 (M+1), which is consistent with C 6 -HSL. Furthermore, peaks at 102 and 99 were observed which correspond to the homoserine lactone ring moiety and the hexanoyl side chain respectively. For absolute con¢rmation, C 6 -HSL was chemically synthesised, as described in Section 2, and shown to possess the same LC-MS fragmentation pattern (Fig. 3) . We were unable to identify molecular ions corresponding to either C 4 -HSL or 3-oxo-C12-HSL.
Discussion
In this study we provide direct evidence that AHLs are present in sputum samples from CF patients colonised by P. aeruginosa and B. cepacia. Furthermore, we report the identi¢cation of the AHLs produced by P. aeruginosa in these samples. By developing a rapid and reliable microtitre plate bioassay for screening concentrated solvent extracts of sputum samples, we have shown that sputum from patients infected with P. aeruginosa contains both short chain AHLs and also a molecule which co-migrates with 3-oxo-C 12 -HSL on thin layer chromatograms. However, we were only able to con¢rm the presence of C 6 -HSL in sputum samples from patients colonised with P. aeruginosa, which was unexpected since, in vitro, this molecule is produced in much smaller quantities than C 4 -HSL [8] or 3-oxo-C 12 -HSL [16] . Nonetheless, P. aeruginosa strains isolated from the sputum produced 3-oxo-C 12 -HSL, C 4 -HSL and C 6 -HSL in vitro. The fact that the reporter plasmid pSB1075 is much more sensitive to low concentrations of 3-oxo-C 12 -HSL than LC-MS is likely to account for our inability to detect this signalling molecule using the latter. Alternatively, AHL production by P. aeruginosa in the CF lung may be di¡erent to that in vitro, perhaps due to the contrasting growth conditions encountered in the CF lung compared to those in laboratory culture conditions. Interestingly Singh et al. [18] have reported that, with respect to de novo synthesis of AHLs in sputum colonised by P. aeruginosa, the ratio of C 4 -HSL to 3-oxo-C 12 -HSL levels is the reverse of that observed for the laboratory strain PAO1 when grown in laboratory medium, yet re£ects that seen within in vitro bio¢lms of the sputum isolates. As a consequence the authors conclude that P. aeruginosa exists predominantly as a bio¢lm within CF sputum. Furthermore, in vitro analysis of strains isolated from the sputum samples showed for one strain that C 6 -HSL was, in fact, the predominant AHL produced. Importantly, transcripts of lasR and lasI, from P. aeruginosa, have previously been detected in CF spu- tum [26] . Moreover, the accumulation of these transcripts correlates with the accumulation of transcripts of target genes which are regulated by lasRI [27] . Although this suggests that the production of AHLs in the CF lung is highly likely, the presence of AHLs in CF sputum had, until now, not been determined. Taken together, this demonstrates that for P. aeruginosa, AHL-mediated quorum sensing systems, which regulate the production of virulence factors that contribute to the deterioration in lung function seen in colonised CF patients, are functional within the CF lung. Of note, sputum extracts from CF patients colonised by S. aureus did not activate any of the biosensors which is consistent with the fact that this pathogen has not been shown to produce AHLs in vitro.
The fact that AHLs are produced in vivo is particularly noteworthy since certain AHLs possess both pharmaco- Fig. 3 . Identi¢cation of C 6 -HSL in sputum from P. aeruginosa-colonised patients by LC-MS. Seven extracts of sputum from patients colonised by P. aeruginosa were pooled and puri¢ed by HPLC. Subsequent LC-MS analysis con¢rmed the presence of C 6 -HSL. The ¢gure shows (i) synthetic C 6 -HSL and (ii) C 6 -HSL from the pooled sample. The peaks indicated by the arrows correspond to the m/z for the molecular ion (M+1: 200) (A), the homoserine lactone moiety (102) (B) and the hexanoyl side chain (99) (C). The structure of C 6 -HSL and its MS fragmentation pattern are shown alongside. The vertical wavy lines show the point of fragmentation in the C 6 -HSL molecule. Numbers correspond to the masses (m/z) of the fragments (A, B, C) in the direction shown by the arrow. logical and immunomodulatory activities and so may function as virulence determinants per se. Speci¢cally, 3-oxo-C 12 -HSL has been shown to modulate T cell and macrophage functions [28] and to and exhibit potent pharmacological activity [29, 30] . Consequently, 3-oxo-C 12 -HSL may not only play a role in the regulation of virulence factor production by P. aeruginosa, but also a¡ect host cell functions to increase the availability of nutrients, whilst down-regulating host defence mechanisms, in order to promote its own survival and growth in vivo.
We are still far from fully understanding how P. aeruginosa and B. cepacia employ quorum sensing to survive and control the onset of disease in the CF lung. Recently, Geisenberger et al. [16] compared the AHL pro¢les of CF clinical isolates grown in vitro and claimed that both the amounts and types of AHLs produced by P. aeruginosa in vitro did not change during chronic colonisation. However, these isolates were grown under laboratory culture conditions. We have found, in some preliminary studies, a possible correlation between the levels of AHLs in vivo and the clinical status of patients (data not shown). Further work, with the inclusion of a larger number of subjects, using the assays described in this paper, is still required in order to draw any conclusions from these observations.
